@article{2cf46bc775c644528d0b053d63f54448,
title = "Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma",
keywords = "CTLA-4, endocrine adverse event, immune checkpoint inhibitor, PD-1, toxicity, MANAGEMENT, IPILIMUMAB, NIVOLUMAB, TOXICITY, 3121 General medicine, internal medicine and other clinical medicine",
author = "Hanna Karhap{\"a}{\"a} and Siru M{\"a}kel{\"a} and Hanna Lauren and Marjut Jaakkola and Camilla Schalin-J{\"a}ntti and Micaela Hernberg",
year = "2022",
month = feb,
doi = "10.1530/EC-21-0562",
language = "English",
volume = "11",
journal = "Endocrine Connections",
issn = "2049-3614",
publisher = "BIOSCIENTIFICA LTD",
number = "2",
}